Boehringer’s discovery team will apply the drug discovery technology to explore targets that are not easily accessible by other discovery platforms.
The XenoGene technology is said to use the power of genetics to identify allosteric inhibitors that are selective for specific protein targets.
CompleGen with a small molecule library, has identified potent allosteric inhibitors for targets where other discovery platforms have failed.
These allosteric inhibitors have been shown to be efficacious and well tolerated in animals, the company claimed.